Nurix Therapeutics (NRIX) Earnings Date & Reports

Key Takeaways

• Nurix Therapeutics reported fiscal third-quarter 2026 revenue of $673.1 million, up sharply from $7.9 million a year earlier.
• Net income reached $549.8 million, or $4.73 per diluted share, compared with a net loss of $86.4 million, or $1.03 per share, in the prior-year quarter.
• The surge was driven by $653.2 million in license revenue from the Roche collaboration and a $10 million development milestone from Sanofi.
• Cash, cash equivalents, and marketable securities climbed to $1.1 billion, extending the company's projected runway into the second half of 2029.
• Nurix dosed the first patient in the registrational Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed/refractory CLL/SLL.

Earnings Context and Why It Matters

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation, an approach that removes disease-causing proteins rather than merely blocking them. For a company that historically reports operating losses, this quarter stands out because of a transformative partnership rather than ordinary performance. The results reflect the completion of its global collaboration with Roche on bexobrutideg, its lead BTK (Bruton's tyrosine kinase) degrader. For investors, the report matters less as a measure of recurring profitability and more as a signal of balance-sheet strength, cash runway, and the clinical momentum behind a potentially best-in-class oncology asset.

Reported Results

For the fiscal third quarter ended August 31, 2026, Nurix reported total revenue of $673.1 million, compared with $7.9 million in the same period a year earlier. The increase was driven primarily by $653.2 million in license revenue recognized from the Roche collaboration, alongside a $10 million development milestone from Sanofi.

Net income for the quarter was $549.8 million, or $4.73 per diluted share, versus a net loss of $86.4 million, or $1.03 per share, a year ago. The reported EPS (earnings per share) far exceeded the consensus estimate of a loss of roughly $0.60 per share, while revenue of $673.1 million dwarfed the approximately $24.4 million consensus figure.

Research and development expenses declined to $79.3 million from $86.1 million, reflecting cost-sharing under the Roche deal. General and administrative expenses rose to $34.4 million from $13.2 million, driven by one-time costs tied to the transaction.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors tracking clinical-stage biotech names like Nurix can use the AI Screener to monitor sector momentum and technical setups alongside fundamental developments.

Market Reaction and Investor Sentiment

The market's response to the headline numbers was muted. Despite a dramatic beat on both revenue and EPS, shares traded modestly lower in after-hours activity following the release. Analysts and investors widely viewed the surge as an accounting event rather than a sign of sustainable profitability, since the figures stemmed from a non-recurring license payment already announced when the Roche deal was disclosed earlier in the year. The durable signal investors focused on instead was the balance sheet: with roughly $1.1 billion in cash and a runway into the second half of 2029, the company gained meaningful time to advance its pipeline without near-term financing risk.

Forward Outlook and Key Factors to Monitor

Looking ahead, the investment narrative for Nurix centers on clinical execution rather than quarterly earnings. The company has moved bexobrutideg into Phase 3 development, having dosed the first patient in the DAYBreak CLL-306 trial comparing the drug against pirtobrutinib in relapsed/refractory CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma). This registrational study is the primary catalyst investors will watch, alongside data from combination studies and the company's immunology expansion plans.

Investors should also monitor operating expense trends, as cost-sharing with Roche partially offsets development spending while Nurix retains a meaningful share of program costs. Progress on NX-1607, its CBL-B (Casitas B-lineage lymphoma proto-oncogene B) inhibitor in Phase 1b expansion, and updates from partnered programs with Gilead, Sanofi, and Pfizer will further shape the outlook.

Finally, the sustainability of the cash position will depend on disciplined spending and the pace of clinical enrollment. With no recurring earnings to anchor valuation, market attention will remain fixed on clinical data readouts and regulatory milestones across the pipeline.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations